Fundamental Research Analysts Give CytoMed Therapeutics (NASDAQ:GDTC) a $4.16 Price Target

Fundamental Research set a $4.16 target price on CytoMed Therapeutics (NASDAQ:GDTC) in a research report released on Tuesday morning,BayStreet reports. The firm currently has a buy rating on the stock.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, CytoMed Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.16.

CytoMed Therapeutics Stock Performance

Shares of CytoMed Therapeutics stock opened at $0.89 on Tuesday. The firm has a fifty day moving average price of $0.91 and a 200 day moving average price of $0.99. CytoMed Therapeutics has a 1 year low of $0.68 and a 1 year high of $3.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.